KRT88P and Hepatitis: This study demonstrated that no HBsAg-negative, anti-HBc-positive rheumatic patient developed HBV-associated hepatitis within the first year after GC pulse therapy with three cases (0.7%) experiencing HBsAg seroreversion in the later stage.